The present invention relates to a drug delivery device with a brushless electrical motor and an actuating assembly, to a method to detect blockage of the actuating assembly, and to a system to provide blockage detection in such a drug delivery device.
A variety of diseases exist that require regular treatment by subcutaneous administration of a medicament, and a number of drug delivery devices have been developed to support a patient in accurately and controllably delivering an amount of drug in a self-administration process. Drug delivery devices include injection devices that are removed from the site of application after each medication event or drug delivery process, as well as infusion devices with a cannula or needle that remains in the skin of the patient for a prolonged period of time. By way of example, diabetes may be treated by administration of insulin by the patients themselves with the help of multivariable-dose insulin injection pens or infusion pumps. Alternatively, patch injectors, wearable injectors or wearable pumps are patched or adhered to the skin of the patient.
Common to all devices for subcutaneous drug delivery is a reservoir to store the fluid medicament, and a fluid path to bring the drug out of the device and into the subcutaneous tissue of a patient. In a majority of injecting or infusion devices the reservoir has a plunger that is mechanically advanced by an actuation assembly - in this case usually a plunger rod - to drive the fluid out of the reservoir into the fluid path and towards the patient. Alternatively, a pump mechanism such as a peristaltic, membrane or piston pump may be used to transport the fluid and effectuate the drug delivery, with a motor-driven actuation assembly generating the mechanical movement.
For drug delivery devices, blockage of the fluid delivery is a major problem which can occur anywhere in the fluid path, e.g. by crystallization of particles in the drug. Such a blockage in the fluid path is also known as occlusion. For safe and reliable drug delivery, detection of blockages and occlusions are an essential requirement.
In many drug delivery devices, an electric motor is used as a driving means. This also means that some electronic circuitry is integrated to control the motion of the motor and consequently the drug delivery. Every blockage in the fluid path, within the reservoir or within the actuating assembly results in a change of torque or driving force at the output of the motor. Therefore, to minimize complexity and cost of such a system, control and supervision of the drug delivery is often realized directly at the motor, for example by analyzing the supply current drawn by motor coils, to avoid extra cost for additional sensors such as optical sensors to supervise the motion of the rotor or pressure sensors to detect excess force in a stall condition.
EP 0341364 B1 describes a drug delivery device with a plunger moving assembly supervision based on the motor current. The motor current is measured during operation of the pump and integrated over a certain time to eliminate spikes. A blockage is reported if the integrated motor current is higher than a pre-defined threshold.
An alternative concept for motor control is known as “back electro-motive force” (Back EMF or BEMF). Sensors are placed at the contacts of an electric motor to sense the voltage induced by motor coils passing the sensor if the motor is rotating. By monitoring these voltages, the motion of the motor can be detected and also used to detect blockage of the delivery. This technique is of special interest if the motor is a stepping motor or a brushless electric (BLDC) motor, where the same coils can be used for driving the motor and for sensing the back EMF voltage signal.
US 2003/0117100 A1 describes a motor control system for a stepping motor using EMF supervision and blockage detection.
US 9,509,243 B2 describes a linear actuation system with back EMF detection of lost steps.
All efforts to supervise the drug delivery and detect blockage back at the driving motor highly depend on the mechanical properties of the actuating assembly or plunger moving assembly. In a system with a rigid and play-free plunger moving assembly any fault along the drive train and the fluid path can immediately be detected at the motor using one of the known techniques. However, with increasing elasticity of the actuating assembly, fault detection such as detection of blockage and occlusion becomes unreliable or even impossible within the accuracy requirements of a drug delivery device. More specifically, in case of an occlusion in the example of a system with a non-rigid plunger moving assembly, the Back EMF voltage signal will not immediately show zero current (complete blockage), because the driving motor will need some time to compress the elasticity of the plunger moving assembly and suppress the rotor movement sufficiently to detect the fault.
WO 2017/017557 A1 describes a method to compensate mechanical play using Back EMF voltage analysis in an actuation system with an elastic element.
To achieve the accuracy of movement and/or fault detection suitable for a drug delivery device, additional sensors and/or mechanisms in the fluid path may be needed, increasing complexity and cost of the drug delivery system.
At the same time it may be advantageous for the mechanical design to allow a controlled amount of elasticity in the plunger moving assembly rather than eliminate the elasticity to avoid the problems described above. The classical linear plunger rod may be replaced by a different mechanism, such as a curved chain of short sticks, a train of balls in a bearing or even a spring, opening up a wide range of new possibilities for the design of drug delivery devices which may be more compact, more ergonomic in outer shape or more cost efficient in manufacturing or use.
There is clearly a need for a system and a method to detect blockage and occlusion in a drug delivery device with a potentially elastic plunger moving assembly, where the blockage is detected directly at the driving motor and no extra sensor is introduced in the reservoir or fluid path.
It is an objective of the invention to provide an improved system and method to detect blockage in a medical fluid delivery device. The improvement explicitly includes providing reliable detection of a blockage in a drug delivery device with a non-rigid actuating assembly. A typical application of the improved blockage detection may for example be in a compact, body-worn drug delivery device with a reservoir and a plunger, where relaxed requirements for rigidity of the plunger moving assembly are most advantageous.
This objective is achieved by a drug delivery device with an electric stepper motor or brushless DC motor (31) operatively connected to the actuating assembly and including at least one driving phase, for example two driving phases, each driving phase having a coil (40), a positive driving contact (41), and a negative driving contact (42) to drive the motor. The drug delivery device further includes a voltage measurement circuitry (55) to measure the voltage at or between the driving contacts (41). The drug delivery device further includes an electronic control unit (20) with a control circuitry (50), an electrical power source, a microprocessor, storage and software configured to control the commutation of the motor (31), to supervise the actuation of the drug delivery device and to initiate an alarming and/or mitigation action if a blockage of the actuating assembly (30) has been detected. This detection is realized with a novel method (160) of evaluating the Back EMF voltage signal (60) of the motor which includes the following steps:
Step 1: commutating the motor (31) by applying a pattern of positive driving voltages (61) to the driving contacts (41), such as repeating a commutation cycle with a succession of all positive driving contacts (41) and all negative driving contacts (42).
Step 2: pausing the driving of at least one driving phase periodically, for example twice per commutation cycle, such as pausing between driving the positive and driving the negative driving contact (42) of the same driving phase, to open a recurring measuring window (63) during which the driving contacts (41) of the paused driving phase are controlled by the voltage measuring circuitry (55) to measure a Back EMF voltage signal (60) at or between said driving contacts (41).
Step 3: measuring or sampling, for a sequence of measuring windows (63), the voltage at or between driving contacts (41) of a driving phase and establishing, for each of the sequence of measurement windows (63), a convergence value (80) representing the Back EMF voltage during said measuring window (63).
Step 4: Periodically calculating, for example once for every commutation cycle k, a blockage indication value BI based on the divergence of convergence values CV measured at different driving contacts. Any mathematical expression may be used to assess said divergence, for example a quantification of maxima and minima, as in the formula BI(k) = max (CP(k) -CN(k)), where CP is a convergence value assigned to a positive driving contact (41), CN is a convergence value assigned to a negative driving contact (42). For the purpose of formulating the calculation of BI, an assigning step may further be included, which includes assigning each convergence value (80) to a positive or to a negative driving contact, such as to the positive or to the negative driving contact of the driving phase paused to perform the voltage measurement, for example assigning the convergence value to the driving contact to which the driving pattern has last been applied before starting the measurement window the convergence value is representing; storing the convergence values in sequences per driving contact, such as with driving phases A and B the sequences CPA, CPB for convergence values at the positive driving contacts PA, PB and the sequences CNA, CNB for convergence values at the negative driving contacts NA, NB.
Step 5: deciding that a blockage of the actuation assembly is present if the blockage indication value BI meets a predefined criterion, for example if the blockage indication value BI exceeds a blockage threshold ±MaxConvDiff for a specified minimum number of commutation cycles k within a specified minimum blockage duration; and
Step 6: initiating an alarm and/or a mitigation action if a blockage has been determined.
In the drug delivery device outlined above, two main aspects of the present disclosure are evident: a method (160) using steps 1 to 6 to detect blockage of the actuation assembly, and a system built into the medical device to implement said method (160). More details about both aspects are specified further below.
The subject matter of the disclosure will be explained in more detail in the following text with reference to exemplary embodiments which are illustrated in the attached drawings, in which:
The reference symbols used in the drawings, and their primary meanings, are listed in summary form in the list of designations. In principle, identical parts are provided with the same reference symbols in the figures.
In the present context, the terms “substance”, “drug”, “medicament” and “medication” are to be understood to include any flowable medical formulation suitable for controlled administration through a means such as, for example, a cannula or a hollow needle, and includes a liquid, a solution, a gel or a fine suspension containing one or more medical active ingredients. A medicament can be a composition including a single active ingredient or a pre-mixed or co-formulated composition with more than one active ingredient present in a single container. Medication includes drugs such as peptides (e.g., insulin, insulin-containing drugs, GLP-1 containing drugs or derived or analogous preparations), proteins and hormones, active ingredients derived from, or harvested by, biological sources, active ingredients based on hormones or genes, nutritional formulations, enzymes and other substances in both solid (suspended) or liquid form but also polysaccharides, vaccines, DNA, RNA, oligonucleotides, antibodies or parts of antibodies but also appropriate basic, auxiliary and carrier substances
The term,,distal” is meant to refer to the direction or the end of the drug delivery device carrying an injection needle or an injection cannula, whereas the term “proximal” is meant to refer to the opposite direction or end pointing away from the needle or cannula.
The term “injection system” or “injector” refers to a device that is removed from the injection site after each medication event or drug delivery process, whereas the term “infusion system” refers to a device with a cannula or needle that remains in the skin of the patient for a prolonged period of time, for example, several hours.
At the core of the present disclosure is a system and a method to detect blockage of an actuating assembly in a medical device with a brushless electric motor by means of a novel way of evaluating Back EMF voltage signals. While blockage detection is a typical system requirement in medical devices, the method of this disclosure may be used for any kind of medical device, with any kind of brushless electric motor and any kind of actuating assembly. In this document, the implementation of disclosure is described in an embodiment of a drug delivery device, more specifically in the example of a wearable patch injector for subcutaneous application of a fluid drug. Any person skilled in the art will have no difficulty applying the same disclosure to the design of a patch pump, mobile pump, stationary pump or any other medical device with an actuating assembly suitable for supervision by analysis of Back EMF voltage signals.
The first three steps of blockage detection according to the invention as disclosed are tightly connected and will be described together in the following paragraphs. The steps are
Electronic circuitry to commutate a brushless DC (BLDC) or stepper motor is well established in prior art.
In
It is common practice in the design of brushless DC and/or stepper motor control to divide the driving time for a specific driving contact into a number of micro-steps, to vary the driving voltage with every micro-step and to spread a pattern of driving voltages over the entire commutation cycle. This means that the driving phases overlap and the driving voltages can be optimized for smoother and more energy efficient commutation.
In an embodiment of the present disclosure, the convergence value may be determined by sampling, during each measuring window (63), the course of the voltage at a driving contact (41) or the course of the voltage difference between two driving contacts (41) of the paused driving phase, and storing the measured values in a set of convergence data (71), starting at a convergence offset (70) from the beginning of the measuring window (63). Sampling is typically performed by triggering the ADC in the measuring circuitry at a constant sampling rate. The drug delivery device may operate with a sampling rate of at least 1 kHz, such as at least 1 MHz, and the convergence data consist of 1 to 1000, for example 16 convergence data values obtained at a convergence offset of 0 to 1000, such as 184 samples within the measuring window. The duration of the measuring window (63) required to let the initial peak pass and determine the convergence value depends on the inductor time constant Tau of the stator coils, on the driving voltage, on the rotation speed of the motor, on the implementation of the measurement circuitry, and on other factors. No minimum offset can hence be specified for the general method. Choosing a longer measurement window may increase, to a limit, the accuracy of calculating the convergence value, but the disadvantages of pausing the commutation will soon become prohibitive. In a practical realization of the present disclosure, the course of the Back EMF voltage signal will be analyzed for a particular motor, a particular control circuitry and a particular measurement circuitry, and the duration of the measurement window will be adjusted accordingly. As discussed above, an ideal Back EMF voltage signal measurement is designed with as little as possible impact on commutation. However, in many cases the duration of the measuring window required for Back EMF voltage analysis may exceed the duration of a micro-step, at least under certain operating conditions, for example at high speed or if the driving voltage pattern is applied with finely pitched micro-steps. To run the blockage detection, the measuring window will typically get priority over commutation at least on a regular selection of commutations, for example for all applications of a driving voltage pattern. This is illustrated in
To arrive at a single convergence value per measuring window, the voltage measurement circuitry will sample the course of the Back EMF voltage signal at the driving contacts of a driving phase over at least part of the measuring window and evaluate a multitude of measured voltages. In an embodiment of the blockage detection according to the present disclosure, a set of convergence data (71), a selection of sampled voltage values starting at a convergence offset (70) after start of the measuring window (63), is used to determine the convergence value (80) of that particular measuring window. In the example of
In step 4 of the blockage detection, the divergence of convergence values assigned to different driving contacts is quantified by calculating a blockage index BI. To specify a mathematical expression for a specific embodiment of the blockage detection, it may be helpful to assign each convergence value acquired in steps 1 to 3 to one of the driving contacts. As the Back EMF voltage at the contacts of a coil changes polarity when a driving voltage is switched off, and as the convergence values may be calculated from positive voltages, the most natural assignment is to assign the convergence values derived from voltage measurements on a positive driving contact to the negative driving contact of the same phase, and the convergence values derived from voltage measurements on a negative driving contact to the positive driving contact of the same phase. This is the logic in a typical embodiment of the present disclosure. Other assignment rules could be used, for example to the same driving contact as the measurement was taken from, provided that values from different driving contacts are consistently kept separate from each other and the assignment allows the analysis of the course of convergence values over a multitude of commutation cycles. The assignment of convergence values to a driving contact may be realized by storing convergence values in separate storage elements so that further processing steps can access the values selectively. The blockage detection according to the present disclosure may include the use of multiple convergence values assigned to the same driving contact over a plurality of commutation cycles. Consequently, the assigning step may include storing sequences of convergence values, for example one sequence per driving contact. In the example of an embodiment with two phases A and B, four driving contacts PA, NA, PB, NB and one measurement window per application of a driving pattern, there are two sequences CPA, CPB, each with a sequence of convergence values assigned to a positive driving contact PA, PB, and two sequences CNA CNB, each with a sequence of convergence values assigned to a negative driving contact NA, NB. Every driving contact is measured once per commutation cycle, hence said sequences typically contain one convergence value per commutation cycle. The term “sequence”, in the context of convergence values, refers to the fact that one particular set of data is updated for a succession of commutation cycles. The number of convergence values stored in a storage element holding a sequence depends on the implementation of the method (160) as described in the present disclosure.
As a main part of step 4, the blockage index is derived from the convergence values. The blockage index may be obtained explicitly by calculating a mathematical expression including or corresponding to a subtraction of values assigned to different driving contacts or groups of driving contacts, or implicitly by applying a statistical analysis or comparison of maximum and minimum values over all driving contacts.
As the divergence of convergence values is especially surprising when observed between convergence values assigned to opposite ends of the same phase, the selection of driving contacts included in calculating the blockage index will typically include both ends of every phase selected, such as both ends of all phases used to drive the motor. Calculating a blockage indication representing the divergence of positive and negative convergence values is not limited to mathematical expressions involving the difference operator, but could be any other means of expressing the difference between the sequences, for example assigning ranges of values, using statistical analysis or applying thresholds, just to name a few. Calculating a blockage indication may also use a combination of explicit and implicit differences, for example by calculating the difference between an actual convergence value and a statistical value like a mean convergence value. Just like the sequences of convergence values, the blockage indication may also be stored sequentially in a storage element of sufficient length to allow further processing, realizing another sliding window of at least one, for example at least ten commutation cycles.
As step 5 of blockage detection, the drug delivery device uses a blockage indication and a blockage criterion to decide if a blockage of the actuation assembly is present. Again, numerous ways exist to specify a criterion, and this criterion obviously depends on how the blockage indication is calculated. Using the example of a simple difference of convergence values on a single phase, exceeding a threshold could be used as an equally simple blockage criterion:
Blockage = YES if BI_1(k) > ±threshold (91) with threshold in the range of, for example, 3 to 6, if using the convergence values as shown in
A more robust blockage detection uses multiple blockage indicators calculated at different times, for example by waiting with a blockage decision until threshold (91) has been exceeded multiple times, for example at least three times in the last ten commutation cycles. Similar to the calculation of the blockage indication, the blockage criterion is not limited to a mathematical expression, but could be any other means of taking a decision based on the blockage indication calculated according the method (160) of the present disclosure, for example by using ranges of values, using statistical analysis or applying variable thresholds, just to name a few.
Once the drug delivery device has reached the decision that a blockage of the actuating assembly is present, the device will forward this information to the patient or to another external component involved in controlling the drug delivery. This is step 6 of the blockage detection and will typically include an alarming action to attract external attention. In a simple embodiment, the alarming is done by changing the status of the drug delivery device, and by a control element reading the status and reacting on the change. Other alarming actions could be a visual or acoustic alarm on the drug delivery device itself, or to communicate the blockage to an external device for further control of the reaction, for example to display a warning on a remote control device or smartphone. Alternatively or additionally, the drug delivery device may react to the blockage with a mitigation action, such as stopping the commutation or reversing the commutation to unblock the actuating assembly, or with providing guidance to the user to effectuate further action.
Starting from a drug delivery device with system for blockage detection as described with steps 1 to 6, a number of further improvements can be included. A first further aspect of the present disclosure relates to smoothing of the convergence values. Looking at
with a running number of commutation cycles k, and N_SCPA(k) being a normalized form of the smoothed convergence value SCPA. Normalized convergence values my further be scaled, for example to represent a percentage, as in
To avoid division by zero when calculating a normalized convergence value, a small non-zero value may be added to the reference RevConv. If an embodiment of the blockage detection includes smoothing of convergence values, the normalization may take place either before or after performing the smoothing, the latter further offering the advantage of easier implementation. The steps of smoothing a series of convergence values, calculating a reference and normalizing the convergence values could also be performed in one step for optimum efficiency in implementation. Just like unprocessed or smoothed convergence values, normalized convergence values may be used to calculate a blockage indication value based on differences of values assigned to positive driving contacts and values assigned to negative driving contacts.
with k as a running number of commutation cycles
As seen when discussing
again with k as a running number of commutation cycles, see
A fourth further aspect of the present disclosure relates to calculating the blockage indication value based on a combination of convergence values from a multitude of phases rather than from pre-calculated blockage indices from individual phases. The divergence of convergence values may be differences between values assigned to both ends of the same phase, but the same divergences may be visible, and quantifiable, by analyzing the convergence values as assigned to any suitable combination of the driving contacts. One example of such a blockage indication value has already been mentioned as BI_1(k), looking for the maximum variation of values over all convergence values as assigned to any driving contacts. This aspect of the present disclosure includes all sorts of statistical analysis or method for comparison in a set of values. Further simple examples of blockage indication values based on unsorted combinations of driving contacts are variations of BI_1 using sequences of smoothed convergence values SCP, SCN or sequences of normalized convergence values N_SCP, N_SCN:
as shown in
Changing the optic from looking at absolute differences to looking at relative deviations or errors, a fifth further aspect of the present disclosure emerges, relating to calculating the blockage indication value as an error or deviation from a normalization reference as described before. Just like selecting convergence values from multiple phases and combining them to a global blocking indication value, the same concept may be applied to normalization. The reference used for normalization may be calculated from multiple phases, stored from earlier commutation cycles, programmed as a fixed constant or obtained in another way to serve the purpose of indicating a deviation of convergence values assigned to positive driving contacts from convergence values assigned to a negative driving contact. When indicating a comparison with a reference, the blockage indication value may be interpreted as an indicator of an error of convergence values. Again, to give a simple example, a blockage indication value may be calculated as the maximum of normalized convergence values for all driving contacts:
However, in BI_12, a large negative error value would be ignored. A further embodiment of a blockage indication may hence get rid of the leading sign of the convergence value and use the concept of a mean square error.
Obviously, using the absolute value of error values would lead to a similar result.
While the description of possible embodiments of the present disclosure in this document has focused on keeping the calculation of the blockage indication values as simple as possible, all sorts of more complicated embodiments may be used with the same effect. The blockage indication value may, for example, use processed or unprocessed convergence values from different commutation cycles rather just one, patterns of values or characteristics of curves may be analyzed, longer term behavior analysis could be included or variation over time like using a non-constant sensitivity for blockage detection. Calculation steps like smoothing, filtering or averaging may be applied in any order or combination. Common to all these variations is that the blockage detection is based on an analysis of differences in Back EMF voltages observed on positive driving contacts and Back EMF voltages observed on negative driving contacts. It is evident that “differences” may not explicitly be expressed as a subtraction in a formula, but could implicitly be included in another mathematical concept like average, mean, correlation, drop, ratio, variance, just to name a few.
While many embodiments have been explained using the example of a wearable patch injector as shown in
While the invention of disclosure has been described in detail in the drawings and foregoing description, such description is to be considered illustrative or exemplary and not restrictive. Variations to the disclosed embodiments can be understood and effected by those skilled in the art and practising the claimed invention, from a study of the drawings, the disclosure, and the appended claims. In the claims, the word “comprising” does not exclude other elements or steps, and the indefinite article “a” or “an” does not exclude a plurality. The mere fact that certain elements or steps are recited in distinct claims does not indicate that a combination of these elements or steps cannot be used to advantage, specifically, in addition to the actual claim dependency, any further meaningful claim combination shall be considered disclosed.
1
10
11
12
13
20
21
22
30
30
a
30
b
30
c
30
d
31
32
32
a
32
b
40
40
a
40
b
41
42
43
44
45
50
51
55
60
61
62
63
70
71
80
90
91
160
Number | Date | Country | Kind |
---|---|---|---|
20205379.9 | Mar 2020 | EP | regional |
This application claims priority to International Application No. PCT/EP2021/079911 filed on Oct. 28, 2021, entitled “SYSTEM AND METHOD TO DETECT DRIVE BLOCKAGE IN A DRUG DELIVERY DEVICE,” which in turn claims priority to European Application No. 20205379.9 filed on Nov. 3, 2020, entitled “SYSTEM AND METHOD TO DETECT DRIVE BLOCKAGE IN A DRUG DELIVERY DEVICE,” each of which is incorporated by reference herein, in their entirety and for all purposes.
Number | Date | Country | |
---|---|---|---|
Parent | PCT/EP2021/079911 | Oct 2021 | WO |
Child | 18310309 | US |